The announcement about Bayers trial follows a similar...

The announcement about Bayers trial follows a similar announcement from Pfizer about their trials. Remember some time ago Astra Zeneca had a compound "Exanta" which was similar and failed late in trials because of liver toxicity.

These new compounds may be better in that regard but irrespective of that they are actually designed to meet a different market segment. They are designed to compete with Warfarin in the at home market for chronic needs like long term management VTE and PE.

Lovenox and Arixtra remain are likely to remain dominant in the hospital market because an injectible gives surgeons and clinicians much better control, is instantly acting, and when your unconcious another needle doesn't really matter much.

Warfarin has been on the market for decades as has lovenox and both seem to co-exist quite happily. I don't see these new drugs as a significant threat. I would be happy to take tharlow's stock at 20c though.